Horseracing Integrity Act of 2019

The Horseracing Integrity Act of 2019, S1820, aims to create a national, uniform standard for anti-doping and medication control in horseracing. This bill directly addresses concerns about drug use and safety within the sport, moving regulatory authority from state-by-state commissions to a national body. This standardization reduces regulatory arbitrage and increases the integrity of races, which could attract more betting interest long-term. However, it also imposes new compliance burdens and potential costs on race tracks and horse owners. This bill does not appropriate specific federal funding. Instead, it establishes the Horseracing Integrity and Safety Authority (HISA), which is funded by fees assessed on racing participants and state racing commissions. Companies involved in drug testing, such as laboratories, stand to gain from increased testing volume. However, the direct financial impact on publicly traded entities is minimal as the horseracing industry is largely privately held or operates through smaller, regional entities. No major publicly traded companies are directly positioned to receive contracts or significant revenue streams from this specific bill. Historically, similar legislation focused on sports integrity has had limited direct market impact on publicly traded companies due to the fragmented nature of sports ownership and the lack of direct federal appropriations. For example, the Professional and Amateur Sports Protection Act (PASPA) repeal in 2018, while a landmark decision for sports betting, primarily benefited sports betting operators like DraftKings ($DKNG) and FanDuel (owned by Flutter Entertainment $PDYPY) by opening new markets, rather than directly impacting the underlying sports organizations through integrity legislation. This bill is procedural, establishing a regulatory framework rather than creating new revenue streams or directly subsidizing the industry. Specific winners are limited to specialized anti-doping laboratories and equine veterinary services that will see increased demand for testing and compliance services. Losers include race track operators and horse owners who face increased compliance costs and potential penalties under the new national standard. No major publicly traded companies are identified as direct winners or losers. The bill was referred to committee in 2019 and has not advanced significantly since, indicating low legislative momentum. What happens next is continued committee review. Given the 2019 date, the bill's advancement is unlikely without reintroduction or significant legislative push. No immediate market action is expected.